- Home
- AFBI vs KLRS Comparison
AFBI vs KLRS Comparison
Compare AFBI & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFBI
- KLRS
- Stock Information
- Founded
- AFBI 1928
- KLRS 2019
- Country
- AFBI United States
- KLRS United States
- Employees
- AFBI N/A
- KLRS N/A
- Industry
- AFBI Major Banks
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AFBI Finance
- KLRS Health Care
- Exchange
- AFBI Nasdaq
- KLRS Nasdaq
- Market Cap
- AFBI 117.0M
- KLRS 129.0M
- IPO Year
- AFBI N/A
- KLRS N/A
- Fundamental
- Price
- AFBI $18.77
- KLRS $2.40
- Analyst Decision
- AFBI
- KLRS Buy
- Analyst Count
- AFBI 0
- KLRS 1
- Target Price
- AFBI N/A
- KLRS N/A
- AVG Volume (30 Days)
- AFBI 6.9K
- KLRS 47.1K
- Earning Date
- AFBI 07-25-2025
- KLRS 08-15-2025
- Dividend Yield
- AFBI 8.00%
- KLRS N/A
- EPS Growth
- AFBI N/A
- KLRS N/A
- EPS
- AFBI 0.91
- KLRS N/A
- Revenue
- AFBI $31,043,000.00
- KLRS N/A
- Revenue This Year
- AFBI N/A
- KLRS N/A
- Revenue Next Year
- AFBI N/A
- KLRS N/A
- P/E Ratio
- AFBI $20.37
- KLRS N/A
- Revenue Growth
- AFBI 4.89
- KLRS N/A
- 52 Week Low
- AFBI $17.00
- KLRS $2.32
- 52 Week High
- AFBI $22.50
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- AFBI 55.25
- KLRS N/A
- Support Level
- AFBI $18.20
- KLRS N/A
- Resistance Level
- AFBI $18.55
- KLRS N/A
- Average True Range (ATR)
- AFBI 0.16
- KLRS 0.00
- MACD
- AFBI 0.02
- KLRS 0.00
- Stochastic Oscillator
- AFBI 61.54
- KLRS 0.00
About AFBI Affinity Bancshares Inc. (MD)
Affinity Bancshares Inc is a holding company of Affinity Bank, a federally chartered stock savings bank that offers a variety of deposit accounts, including checking accounts, savings accounts, and certificate of deposit accounts. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate loans, commercial and industrial loans, residential real estate loans, construction and land loans, and consumer loans. It also invests in securities, which consist of mortgage-backed securities and obligations issued by United States government-sponsored enterprises and Federal Home Loan Bank stock.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.